Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy

Sagawa, Toshihiko; Kakizaki, Satoru; Tomizawa, Takashi; Nakayama, Tetsuo; Tanaka, Hiroto; Tojima, Hiroki; Sato, Ken; Kusano, Motoyasu; Okamura, Shinichi; Yamada, Masanobu

doi:10.1111/codi.13258

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the fecal lactoferrin level has been proved to be a useful tool for diagnosing IBD (37) and differentiating between active and inactive disease (42,43). Furthermore, the fecal lactoferrin level has been found to correlate well with the endoscopic severity of colonic IBD (16).…”

Section: Resultsmentioning

confidence: 99%

“…Sagawa et al stated that fecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker in differentiating patients with inactive and active ulcerative colitis from healthy controls (43). During intestinal inflammation neutrophils infiltrate the mucosa and markedly increase lactoferrin levels that can be readily measured in feces or gut lavage fluid (15,16).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

2017

Int. J. Curr. Res. Med. Sci.

View full text Add to dashboard Cite

Aims: to analyze the usefulness of fecal lactoferrin, fecal calprotectin, transforming growth factor-B1,Endoscopic Activity Index, Clinical Activity Index, C-reactive protein, and blood leucocytes in monitoring disease activity in Egyptian patients with ulcerative colitis. Methods: One hundred and twenty patients with ulcerative colitis were enrolled and scored according to the endoscopic part of the Rachmilewitz Index. Patients and controls: Patients and controls provided fecal and blood samples for measuring Lactoferrin, calprotectin, TGF-B1, CRP, and leucocytes. Results: The values in ulcerative colitis patients (n = 120) compared to controls (n = 30): Fecal lactoferrin: 703.6±657.6 versus7.01±3.9 µg/g, calprotectin: 867.4±561.2 versus 36.3±15.3 μg /g, TGF-B1: 386.9±246.7 versus 5.9±1.8 pg /ml, CRP:19.4±14.7 versus 3.2±0.9 mg/L, blood leucocytes: 11.6±3.8 versus 6.8±1.9 g/L ( for all P< 0.001). Endoscopic disease activity correlated significantly with lactoferrin (Spearman's rank correlation coefficient r =0.949), calprotectin (r = 0.923), TGF-B1 (r = 0.918), Clinical Activity Index (r = 0. 761), CRP (r = 0.851), and blood leucocytes (r = 0.681). Fecal lactoferrin, calprotectin and TGF-B1 levels were significantly lower in ulcerative colitis patients with inactive disease ( endoscopic score 0 -3, Lactoferrin 48.7±24.9 µg/g, calprotectin 81.5 ± 48.8 μg / g, TGF-B1 42.5 ± 36.5 pg/mL , P < 0.001 for both lactoferrin and calprotectin, but P <0.059 for TGF-B1), compared to patients with mild ( score 4 -6, lactoferrin 465.7 ± 217.4 µg/g, calprotectin 420.4 ±244.8 μg/g, TGF-B1 269.6 ± 80.3 pg/mL, P < 0.001 ), moderate ( score 7 -9, lactoferrin 678.7 ± 258.6 µg/g, calprotectin 1074.9 ± 303.5 μg/g, TGF-B1 391.5 ± 56.8 pg/mL, P < 0.001 ), and high disease ( score 10 -12 , lactoferrin 1624.5 ± 327.2 µg/g, calprotectin 1466.5.2 ± 31.5 μg/g, TGF-B1 690.9 ± 160.1 Pg/ mL, P < 0.001). The overall accuracy for detection of histopathological active disease was 96.9 % for fecal lactoferrin, 96.6 for fecal calprotectin, 94.5 % for TGF-B1, 90 % for Endoscopic Activity Index, 87 % for Clinical Activity Index, and 65 % for both blood leucocytes and CRP. Conclusion: Fecal lactoferrin, fecal calprotectin and TGF-B1 correlated significantly with endoscopic disease activity, clinical activity index, CRP, and blood leucocytes. Furthermore, lactoferrin and calprotectin were suitable markers that can differentiate endoscopically and histopathologically inactive from active disease. Also TGF-B1 was used as a useful marker to distinguish mild from moderate and high active disease. Thus, these three biomarkers may be used for monitoring ulcerative colitis activity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

2017

Int. J. Curr. Res. Med. Sci.

View full text Add to dashboard Cite

show abstract

Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis

Bamias

Zampeli

Domènech

2022

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults

et al. 2020

View full text Add to dashboard Cite

Mucosal healing (MH) is the key therapeutic target of inflammatory bowel disease (IBD). The evaluation of MH remains challenging, with endoscopy being the golden standard. We performed a comprehensive overview of the performance of fecal-, serum-, and urine-based biochemical markers in colonic IBD to find out whether we are ready to replace endoscopy with a non-invasive but equally accurate instrument. A Pubmed, Web of Knowledge, and Scopus search of original articles as potential MH markers in adults, published between January 2009 and March 2020, was conducted. Finally, 84 eligible studies were identified. The most frequently studied fecal marker was calprotectin (44 studies), with areas under the curves (AUCs) ranging from 0.70 to 0.99 in ulcerative colitis (UC) and from 0.70 to 0.94 in Crohn`s disease (CD), followed by lactoferrin (4 studies), matrix metalloproteinase-9 (3 studies), and lipocalin-2 (3 studies). The most frequently studied serum marker was C-reactive protein (30 studies), with AUCs ranging from 0.60 to 0.96 in UC and from 0.64 to 0.93 in CD. Fecal calprotectin is an accurate MH marker in IBD in adults; however, it cannot replace endoscopy and the application of calprotectin is hampered by the lack of standardization concerning the cut-off value. Other markers are either not sufficiently accurate or have not been studied extensively enough.

show abstract

Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy

Abstract: The faecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker during GMA therapy in patients with ulcerative colitis.

Cited by 4 publications

References 29 publications

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

Fecal Lactoferrin, Fecal Calprotectin, Transforming growth factor-b1, and CRP in Evaluation of Disease Activity in Egyptian patients With Ulcerative colitis

Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis

Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults

Contact Info

Product

Resources

About